Compare KraneShares CSI China Internet ETF (KWEB) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Merck & Co., Inc. — how do they compare? KraneShares CSI China Internet ETF trades at $24.93 (market cap $4.37B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 80.4× KraneShares CSI China Internet ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while KraneShares CSI China Internet ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and Merck & Co., Inc. for 98 Days on average.
| KWEB | MRK | |
|---|---|---|
Market Cap | $4.37B | $351.28B |
Volume | 13,393,361 | 7,969,665 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $156.43 |
52-Week Low | $23.63 | $82.49 |
Typical Hold Time | 57 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB, the KraneShares CSI China Internet ETF, trades at $24.025, down 1.25% amid bearish technical signals with all 13 moving averages indicating sell pressure. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption, though recent institutional activity shows mixed positioning with some firms reducing stakes while others increase exposure ahead of potential trade developments.
The outlook remains cautious given China's macroeconomic pressures and ongoing U.S.-China trade tensions, though corporate profits surged 26% in Q2 2026. Key risks include global protectionism against Chinese exports and regulatory uncertainty, while potential trade agreement progress could provide catalysts for the battered Chinese internet sector.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
